http://www.emedicine.com/med/topic3552.htm
{...snip...}
Mortality/Morbidity: Despite recent advances in the management of patients with heart failure, morbidity and mortality rates remain high, with an estimated 5-year mortality rate of 50%.
* Assigning figures for inpatient mortality rates is difficult because the causes and the severity of heart failure vary considerably. The most recent estimates of inpatient mortality rates indicate that death occurs in up to 5-20% of patients.
* Hypoxemia that occurs in decompensated CHF, which may be severe, may result in myocardial ischemia or infarction.
* Respiratory failure with hypercapnic respiratory acidosis may occur in severe decompensated CHF, requiring mechanical ventilation if medical therapy is delayed or unsuccessful. Endotracheal intubation and mechanical ventilation are associated with their own risks, including aspiration (during the intubation process), mucosal trauma (more common with nasotracheal intubation than orotracheal intubation), and barotrauma.
* In patients with CHF, the risk of cardiac sudden death from ventricular tachycardia (VT) or ventricular fibrillation is considerable, and the degree of risk is correlated with the degree of decompensation and the degree of LV dysfunction. Recognition of the role of ventricular arrhythmias and advances in their treatment have resulted in decreased mortality rates in individuals with CHF.
* Progressive renal insufficiency due to decreased renal blood flow and GFR are common in patients with long-standing CHF.
* Liver dysfunction due to passive hepatic congestion is particularly common in patients with right-sided CHF with elevated right ventricular (RV) pressure that is transmitted back into the portal vein.
o Mild jaundice, mild abnormalities in coagulation, and derangements in liver metabolism of medications, some of which are used in the treatment of heart failure, may result from this liver dysfunction.
o Toxic levels of medications such as warfarin, theophylline, phenytoin, and digoxin can result from delayed liver metabolic clearance of these drugs in the presence of decompensated CHF, thereby leading to potentially fatal bleeding, cardiac dysrhythmias, and neurologic abnormalities.